CROMA-PHARMA
27.1.2022 15:28:08 CET | Business Wire | Press release
Croma-Pharma (Croma), today announced that the decentralized procedure for its botulinum toxin to gain market authorization in Europe has been accomplished. This important step is the basis to complete Croma’s already comprehensive portfolio.
Croma’s botulinum toxin submission in Europe is based on the data of 3 completed randomized, placebo-controlled phase III trials that enrolled a total of >1000 subjects in Europe and the US. National phases to grant the market authorization across Europe are following now.
A game changer for Croma-Pharma and the aesthetic industry
By adding its own botulinum toxin to the already broad portfolio Croma catapults itself to a new level within the aesthetic industry.
Offering already a wide selection of HA fillers, PDO threads, PRP and scientific skincare products, the botulinum toxin was the missing piece to compete with world leaders in this sector.
“We are pleased to announce that our toxin has now accomplished the decentralized procedure in Europe and will continue with the market authorization in major European countries in the next months. With this, we will now be able to complete our portfolio to meet all the needs of our customers”, Managing Director Andreas Prinz points out.
Partnership with Hugel
Croma has licensed the product from the Korean toxin producer Hugel Inc. for Europe and established a joint venture company in 2018 with Hugel, Inc., in order to develop and commercialize Croma’s HA filler products together with Hugel’s botulinum toxin product in the US, Canada, Australia and New Zealand.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high-quality skincare technologies in its core strategic markets.
About Hugel, Inc.
Established in Korea in 2001, Hugel is a global leader in medical aesthetics providing botulinum toxin formulation under different brand names such as BOTULAX and LETYBO in numerous countries across the world. Dedicated to provide proven, high quality medical aesthetic solutions that satisfy both consumers’ and practitioners’ needs, Hugel is leading the Korean market with its botulinum toxin.
PR2LET0122GMXb
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005535/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Reports Q3 2026 Results, with Growth in its Specialty Ingredients & Solutions Business and Solos Activity Net Profit and Cashflow from Operating Activities9.11.2026 11:18:00 CET | Press release
Group revenues for the quarter grew 7% reaching US$98.4 million.SIS revenues (Specialty Ingredients & Solutions) grew 30% in Q3 reaching US$20 million.Adjusted EBITDA1 for the SIS grew 37% reaching US$4.3 million, reflecting an adjusted EBITDA margin of 21.4%.Juice Solutions revenues grew 2% in the quarter to US$78 million, improvement in adjusted EBITDA margin to 11.0%.Group’s adjusted net profit grew 34% reaching US$4.2 million.Cashflow from operating activities in the quarter was strong, increasing to US$16.7 million.Last week, the Company announced a strategic acquisition, of BOK, a South African company that produces natural ingredients, high value grape based specialty using circular economy principles. Regulatory News: Tsahi Barak, Chairman of the Board and CEO of the Company, commented: "We are pleased to report another quarter of growth across all key operating parameters, alongside an important strategic acquisition. We continue to make substantial investments in production i
Logistics Reply named a Leader in the IDC MarketScape: Worldwide Warehouse Management for Retail and Manufacturing9.11.2026 10:00:00 CET | Press release
Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Warehouse Management for Retail 2026 Vendor Assessment (doc #US53701926, October 2026) as well as in the IDC MarketScape: Worldwide Warehouse Management for Manufacturing 2026 Vendor Assessment (doc #US53013526, October 2026). The reports evaluate vendors based on strategy and product capabilities, looking at both quantitative and qualitative criteria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109197861/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Warehouse Management for Retail and Manufacturing. LEA ReplyTM is Logistics Reply’s cloud-native warehouse
SWISSto12 passes critical design review of dual-band 5G antennas for UNIVITY satellites9.11.2026 09:00:00 CET | Press release
The milestone clears the way for flight hardware production, bringing UNIVITY closer to delivering both broadband and direct-to-device 5G services from a single satellite architecture. SWISSto12, a leading enabler of the new space economy, today announced it has passed the Critical Design Review (CDR) for the S- and Ka-band phased array antennas for UNIVITY’s 5G non-terrestrial network (NTN) demonstration satellites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109823601/en/ SWISSto12's S- and Ka-band phased array antennas pass Critical Design Review SWISSto12 is developing two active antennas for UNIVITY: an S-band direct radiating array (DRA) for direct-to-device services, connecting standard 5G phones straight to the satellite, and a Ka-band DRA operating at 26 GHz for broadband services and feeder links. Both are built for 5G NTN applications, allowing one single satellite to carry both broadband and direct-to-devic
Arrow Electronics lancerer en ny forretning, Capstone, for at øge fokus på IP&E-løsninger9.11.2026 07:00:00 CET | Pressemeddelelse
Arrow præsenterer den nye forretning på electronica-messen i München (10.-13. nov) Arrow Electronics, Inc. (NYSE:ARW) annoncerede i dag lanceringen af Capstone, en global forretning dedikeret til interconnect, passiver og elektromekaniske (IP&E) produkter, løsninger og services. Med Capstone skaber Arrow en fokuseret og specialiseret go-to-market-tilgang for IP&E idet det teknologisegment bliver mere kritisk for systemets ydeevne, pålidelighed og forsynings sikkerhed. Capstone er designet til at gøre IP&E nem at specificere, indkøbe og skalere. Kunder vil få fordelen ved dedikeret IP&E ressourcer, hurtig beslutningstagning og bred teknisk viden, både på on-board og off-board produkter. Med et fokuseret brand kan Capstone tilbyde kunderne mere målrettet rådgivning og støtte gennem hele processen – fra de første designovervejelser til den færdige produktion. Det giver kunderne et bedre grundlag for at træffe de rigtige beslutninger, mindske risikoen undervejs og skabe de bedste skalerbar
Avanzanite Announces Exclusive Licence Agreement to Commercialise Zemcelpro® in Europe9.11.2026 07:00:00 CET | Press release
Zemcelpro is authorised in the European Union for eligible adults with blood cancers who need an allogeneic stem cell transplant and have no other suitable donor cells available. Avanzanite secures exclusive commercialisation rights to Zemcelpro across 32 countries covering the European Economic Area, UK and Switzerland including potential indication expansion. Avanzanite will become the EU marketing authorisation holder following regulatory transfer and support a planned Phase 3 trial. Zemcelpro becomes Avanzanite’s fifth rare disease launch and first advanced therapy medicinal product (ATMP). Avanzanite Bioscience B.V. (“Avanzanite” or “Company”) a European pharmaceutical company focused on rare diseases, today announced an exclusive licence agreement with Montreal-based Cordex Biologics, an ExCellThera company (“ExCellThera”), a leader in enhanced blood stem cell therapies, to commercialise Zemcelpro®. Zemcelpro received conditional marketing authorisation from the European Commissi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom